GlassScriptPhysician profile
Sadeem Mahmood
NPI 1245299924
$10,683.00
in general payments reported to CMS, 2019-2025
39 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $1,421 · 2021: $1,220 · 2022: $1,894 · 2023: $2,322 · 2024: $1,405 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633 · Travel and Lodging: $1,478 · Consulting Fee: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,633.37 |
| Travel and Lodging | $1,477.69 |
| Consulting Fee | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,798.09 | 2020-2025 | Acticor 7 Vr-T Dx, Pantera Leo |
| Medtronic, INC. | $1,719.73 | 2022-2024 | Micra, Turbohawk, Abre |
| Abbott Laboratories | $1,617.84 | 2019-2025 | Xience Skypoint, Diamondback Peripheral, Esprit |
| Terumo Medical Corporation | $700.00 | 2024 | Navicross |
| Amgen INC. | $590.19 | 2019-2025 | Repatha, Repatha |
| Siemens Medical Solutions USA, INC. | $532.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $439.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $376.76 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $338.79 | 2021-2025 | Verquvo |
| Cardiovascular Systems INC. | $312.39 | 2019-2022 | |
| Philips North America LLC | $297.23 | 2020-2024 | (Ck4) Mcot |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.68 | 2019-2024 | Lifevest |
| Cook Medical LLC | $190.62 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $186.06 | 2025 | Rhythm Express |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.48 | 2021-2024 | Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadeem Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.